Immunodeficiency News and Research

RSS

Immunodeficiency (or immune deficiency) is a state in which the immune system's ability to fight infectious disease is compromised or entirely absent.

Researchers discover gene mutation linked with lymphoedema, leukaemia

Researchers have discovered a gene that when mutated can cause lymphoedema (swollen limbs due to a failure of the lymph system), immune abnormalities, deafness and leukaemia.

5 Sep 2011

Researchers discover protein signals responsible for preserving anti-viral antibodies

Our immune system is capable of a remarkable feat: the ability to remember infections for years, even decades, after they have first been encountered and defeated. While the antibodies we make last only about a month, we retain the means of making them for a lifetime.

3 Sep 2011

Severe combined immunodeficiency treated successfully with gene therapy

Gene therapy can offer a cure for a rare condition that causes children’s immune systems to fail. In this rare condition, known as Severe Combined Immunodeficiency (SCID), inherited genetic mutations mean that babies are unable to fight off infection, severely limiting their chances of surviving more than a few years. Severe combined immunodeficiency (SCID) is a rare genetic disorder estimated to affect between 1 in 200,000 and 1 in 1,000,000 live births

26 Aug 2011

GeoVax receives NIH-NIAID grant for HIV/AIDS vaccine program

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced receipt of a $3.6 million annual notice of award for the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) Grant supporting GeoVax's HIV/AIDS vaccine program.

17 Aug 2011

FDA clears Inhibikase IkT-001 Phase II trial to treat JCV infection in multiple sclerosis patients

Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).

17 Aug 2011

Aeras, OETC announce initiation of new TB vaccine Phase IIb trial in patients with HIV

Aeras and the Oxford-Emergent Tuberculosis Consortium (OETC) announce today the start of a Phase IIb proof-of-concept efficacy trial of a new investigational tuberculosis (TB) vaccine that involves people living with the human immunodeficiency virus.

11 Aug 2011

Once daily HIV ‘combo’ drug approved in U.S.

The U.S. Food and Drug Administration (FDA) has given its approval to a once daily HIV treatment that combines Gilead Sciences Inc.'s drug Truvada with Johnson & Johnson's drug Edurant, Gilead said Wednesday.

11 Aug 2011

The graying of HIV and AIDS

At 57, Bill Nissley he still leads an active life - traveling, teaching tennis to budding young players, conversing in five languages with whomever he can find. But Nissley is growing older, and that in itself is astounding. The Santa Monica resident has coexisted with human immunodeficiency virus since testing positive in 1987, which led to him contracting acquired immune deficiency syndrome in 1998.

10 Aug 2011

Smoking figures show decrease in heavy smokers but rise in teenage and light smokers

A new study reveals that American high school students are unlikely to be heavy smokers, but casual and occasional smoking is on the rise. The study warns that even light smoking may be injurious to health.

8 Aug 2011

Scientists identify small molecule inhibitors of cellular uptake

Scientists from Freie Universität Berlin and the NeuroCure Cluster of Excellence led by biochemist Volker Haucke in collaboration with colleagues from Australia and the Leibniz Institute for Molecular Pharmacology in Berlin have developed small molecules that inhibit the internalization of important signaling molecules but also of pathogenic organisms such as the immunodeficiency virus and bacteria into cells.

5 Aug 2011

Study looks at HIV infections in Middle East and North Africa

New research shows that sex between men (MSM - Men who have Sex with Men) is responsible for more than a quarter of new HIV infections in parts of the Middle East and North Africa.

3 Aug 2011

Preventive health services at no additional cost for women: HHS

Historic new guidelines that will ensure women receive preventive health services at no additional cost were announced today by the U.S. Department of Health and Human Services (HHS).

1 Aug 2011

PPTA applauds introduction of 'Preserving Access to Orphan Drugs Act'

The Plasma Protein Therapeutics Association (PPTA) applauds the introduction of bipartisan legislation, the Preserving Access to Orphan Drugs Act (H.R. 2672) and (S. 1423), which will safeguard the development of drugs and therapies that treat patients with rare diseases by eliminating barriers to innovation.

30 Jul 2011

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

FDA approves U.S. launch of Wiskott-Aldrich gene therapy clinical trial

The U.S. Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome.

22 Jul 2011

Baxter net income increases 15% to $615 million for second quarter 2011

Baxter International Inc. today announced strong financial results for the second quarter of 2011, and raised its financial outlook for full-year 2011.

From Baxter International Inc. 21 Jul 2011

Cell biologists identify infection mechanism of adenoviruses

Mucosal epithelia do not have any receptors on the outer membrane for the absorption of viruses like hepatitis C, herpes, the adenovirus or polio, and are thus well-protected against pathogenic germs. However, certain viruses, such as the human immunodeficiency virus HIV, still manage to enter the body via the mucous membrane.

21 Jul 2011

Boosted REYATAZ shows durable viral suppression in women with HIV

Bristol-Myers Squibb Company announced results from a long-term, retrospective, European cohort study, which included 1,294 antiretroviral (ARV)-experienced patients from Germany, France and Sweden, that were presented today at the Sixth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.

21 Jul 2011

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Janssen Therapeutics, Division of Janssen Products, LP, presented today 96-week findings from two pivotal Phase 3 clinical trials, known as ECHO and THRIVE, comparing the efficacy, safety and virology profile of its non-nucleoside reverse transcriptase inhibitor EDURANT tablets versus efavirenz (EFV) in antiretroviral treatment-naive, HIV-1-infected adults.

20 Jul 2011

Johnson & Johnson second quarter sales increase 8.3% to $16.6 billion

Johnson & Johnson today announced sales of $16.6 billion for the second quarter of 2011, an increase of 8.3% as compared to the second quarter of 2010.

19 Jul 2011